A Phase 3 interventional study of Olokizumab and Standard therapy in COVID-19, sponsored by R-Pharm. Status unknown at 5 sites in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-13.
Sponsored by R-Pharm · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 144 studies in COVID-19 with a site in Russian Federation — 4 open to participants now, 9 under way, 1 of them phase 3. COVID-19 · Russian Federation.
Among the 144 studies in COVID-19 with a site in Russian Federation, this one is the 53rd largest by enrollment of the 105 interventional ones that give a count, is one of 38 that started in 2021, is one of 40 in phase 3, and was the 109th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →4 of the 144 studies in COVID-19 with a site in Russian Federation are open now. Recruiting first, the newest first:
Masaryk University · Sites in Russian Federation, United States, Canada and 11 more countries
Ages 18+
Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department · Sites in Russian Federation
Ages 18+ · Healthy volunteers
I.M. Sechenov First Moscow State Medical University · Sites in Russian Federation
Ages 18–80
Valenta Pharm JSC · Sites in Russian Federation
Ages 18–45 · Healthy volunteers
A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
144 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 41 · Phase 3 51 · Phase 4 6
First in 2018; this study’s year is marked. 38 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 198 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 198 across the 105 interventional studies, 220 across the 39 observational. Of the 107 that completed or were terminated, 27 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 144 have an industry lead sponsor. The 10 most frequent:
R-Pharm is the lead sponsor of 58 studies on the registry; 2 are open to participants now.
R-Pharm has 8 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
1 of the studies in COVID-19 with a site in Russian Federation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04522076National Research Center for Preventive MedicineProspective Hospital Registry of Patients With Suspected or Confirmed Coronavirus Infection (COVID-19) and Community-acquired Pneumonia | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 144 studies in COVID-19 with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the efficacy and safety of Artlegia (INN: olokizumab) new dosing regimen in patients with moderate coronavirus infection (COVID-19) with signs of hyperinflammation.
This study is a multicentre, open-label, randomized, comparative, parallel group, active-controlled clinical trial.
The study has an adaptive design. According to the initial calculation of the sample size it was planned to include about 204 patients in the study. After interim analyzing of the data of the first 100 randomized patients a decision about the final sample size was made. The size of the intent-to-treat (ITT) population for the final efficacy analysis at the primary endpoint is 180 patients. Taking into account the probability of dropping out up to 10% of patients, 198 patients were planned to be randomized into the study, no more than 220 patients were planned to be screened.
The study will include the following periods:
Eligible patients will be randomized to one of 2 treatment groups to receive olokizumab (OKZ) 128 mg i.v. infusion (one or two single doses) against the background of standard therapy, or standard therapy alone.
In OKZ group study drug olokizumab 128 mg is administered as a single intravenous infusion. A comprehensive assessment of the clinical and laboratory response is performed daily within 5 days (120 hours) after the first injection. If there is no response to therapy or the response is insufficient, the repeated dose of OKZ, 128 mg, is administered.
As standard anti-inflammatory therapy, patients in both groups will receive baricitinib (at the standard recommended dose of 4 mg / 1 time per day, for 7 days) and low doses of glucocorticosteroids (dexamethasone at doses of 4-20 mg / day or methylprednisolone at a dose of 1 mg / kg / intravenous injection every 12 hours).
With an observed clinical deterioration (fever increase, dyspnea, oxygen saturation decrease, the appearance / increase in the need for oxygen support) after repeated infusion of OKZ in the main group (at least 24 hours from the first infusion started), or after 24 hours or more from the start of therapy in the comparison group, the patient is considered "not responding" to therapy and requiring another anti-inflammatory treatment regimens.
Standard therapy also includes etiotropic therapy for COVID-19, as well as symptomatic and anticoagulant therapy.
Etiotropic therapy. Favipiravir will be used in recommended dosage regimens according to temporary guidelines "Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)" of the Ministry of Health of Russian Federation.
Patients who have started etiotropic therapy with favipiravir or remdesivir prior to randomization will continue the initiated treatment.
Сlinical status will be assessed daily in the first 10 days, then on days 14, 21, 28, 45, 60, 90 and 180, vital signs - three times daily in the first 5 days, once daily on days 6-10, then on days 14 and 28, chest CT - on days 7, 14 and 28; laboratory parameters - on days 1 - 5, 10, 14, 28.
On day 7 primary endpoint of patient's clinical recovery (defined as score of 3 or less on a 10-point ordinal scale of clinical improvement) will be assessed. The last patient's visit to the study site will be the visit on Day 28. On Days 45, 60, 90 and 180 the phone follow-up will be performed.
In olokizumab group, eligible subjects will be selected to participate in pharmacokinetic analysis. Blood samples for the evaluation of olokizumab pharmacokinetics will be taken before the infusion of olokizumab and in 2 h, 4 h, 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 144 h, 168 h, 192 h, 216 h, 240 h, 336 h and 672 h after the first administration of the drug (since the start of infusion).
Expected study duration for each patient will be 182 (± 2) days, including screening periods (2 days), therapy and short-term follow-up (28 (± 2) days), and long-term extended follow-up (152 (± 2) 2 days).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Moderate COVID-19. Moderate course of the disease is characterized by pneumonia on chest computed tomography (CT) (CT-1,2 stages) and body temperature > 38 °C, in combination with 1 or more of the following:
The presence of signs of hyperinflammation. Signs of hyperinflammation are body temperature ≥ 38 °C for 2 days or more, combined with 1 or more of the following:
Additional inclusion criteria for the pharmacokinetics (PK) subgroup:
Exclusion Criteria:
Signs of a severe or extremely severe course of COVID-19, such as:
Any of the following laboratory abnormalities:
Recent (less than 5 half-lives) or prescribed at screening:
Immunosuppressive drugs (including, but not limited to):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subject randomized to receive intravenous infusion of 0,8 ml solution of Olokizumab, one (128 mg), or two (256 mg) doses, in addition to standard therapy in line with the current temporary guidelines "Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)" of the Ministry of Health of Russian Federation. Standard therapy includes: * Baricitinib, p.o., 4 mg once daily for 7 days * Favipiravir, p.o., * for patients weighing \<75 kg: 1600 mg twice daily on Day 1, then 600 mg twice daily from the 2nd to the 10th day; * for patients weighing ≥ 75 kg: 1800 mg twice daily on Day 1, then 800 mg twice daily from the 2nd to the 10th day; (Patients who have started etiotropic therapy with favipiravir or remdesivir prior to randomization will continue the initiated treatment.) * dexamethasone at doses of 4 - 20 mg / day or methylprednisolone at a dose of 1 mg / kg / intravenous injection every 12 hours.
Drug: Olokizumab · Drug: Standard therapy
Standard therapy in line with the current temporary guidelines "Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)" of the Ministry of Health of Russian Federation including: * Baricitinib, p.o., 4 mg once daily for 7 days * Favipiravir, p.o., * for patients weighing \<75 kg: 1600 mg twice daily on Day 1, then 600 mg twice daily from the 2nd to the 10th day; * for patients weighing ≥ 75 kg: 1800 mg twice daily on Day 1, then 800 mg twice daily from the 2nd to the 10th day; (Patients who have started etiotropic therapy with favipiravir or remdesivir prior to randomization will continue the initiated treatment.) * dexamethasone at doses of 4 - 20 mg / day or methylprednisolone at a dose of 1 mg / kg / intravenous injection every 12 hours.
Drug: Standard therapy
Olokizumab, 128 mg, solution for subcutaneous administration 160 mg/mL
Standard treatment including: * Baricitinib, 4 mg, film coated tablets * Favipiravir, 200 mg, film coated tablets * Dexamethasone IV or IM OR Methylprednisolone IV
Clinical recovery rate at day 7
Clinical recovery defined as score of 3 or less on a 10-point ordinal scale of clinical improvement. (From 0 "Healthy - no clinical manifestations, no viral RNA detected" to 10 "Death".) 7 days are counted from the day of the first administration / intake of study therapy / comparison therapy, depending on study group. Criteria for transition from category "4" to category "3" (criteria for potential discharge): body temperature \< 37 °C; respiratory rate ≤ 20 per minute; SpO2 ≥ 95% without oxygen support, CRP \< 10 mg/l. If any emergency procedures should be prescribed and/or signs of progression on CT are detected, the patient cannot be discharged/transferred to category "3". (In the case of the "rescue" therapy use or the development of clinical deterioration (an increase in the score by 1 point or more) during the follow-up period in a previously recovered patient, the patient is not considered as a "responder", i.e., who has reached the primary endpoint.)
Time frame: Up to day 7
Rate of clinical deterioration by at least 1 point from the baseline ordinal score at day 28, depending on study group
Rate of clinical deterioration by at least 1 point from the baseline ordinal score at day 28, depending on study group
Time frame: Up to day 28
CRP normalization rate
Normalization is defined as CRP blood level within normal range (\< 10 mg/l), assessed on days 5, 10, 14, 28, depending on study group.
Time frame: Up to Day 28
Ferritin normalization rate
Normalization is defined as ferritin blood level within normal range, assessed on days 5, 10, 14, 28, depending on study group.
Time frame: Up to Day 28
D-dimer normalization rate
Normalization is defined as D-dimer blood level within normal range, assessed on days 5, 10, 14, 28, depending on study group.
Time frame: Up to Day 28
Mean CRP levels
Mean CRP levels assessed on days 5, 10, 14, 28, depending on study group
Time frame: Up to Day 28
Mean ferritin levels
Mean ferritin levels assessed on days 5, 10, 14, 28, depending on study group
Time frame: Up to Day 28
Mean D-dimer levels
Mean D-dimer levels assessed on days 5, 10, 14, 28, depending on study group
Time frame: Up to Day 28
Rate of prescribing other anti-inflammatory therapy regimens (rescue therapy), depending on study group
Rate of prescribing other anti-inflammatory therapy regimens (rescue therapy), depending on study group
Time frame: Up to day 28
Rate of clinical deterioration by at least 1 point from the baseline ordinal score at day 7, depending on study group
Rate of clinical deterioration by at least 1 point from the baseline ordinal score at day 7, depending on study group
Time frame: Up to day 7
Clinical recovery rate at day 14
Clinical recovery defined as score of 3 or less on a 10-point ordinal scale of clinical improvement, 14 days are counted from the day of the first administration / intake of study / comparison therapy by treatment group
Time frame: Up to day 14
Cumulative incidence of transfer to intensive care unit (ICU), transfer to mechanical ventilation, development of ARDS and / or death, at day 28
Cumulative incidence of transfer to ICU, transfer to mechanical ventilation, development of ARDS and / or death, at day 28
Time frame: Uo to day 28
Incidence of progression on chest CT at day 28
Incidence of progression on chest CT at day 28, depending on study group
Time frame: Up to day 28
Rate of transfer to ICU at day 28
Rate of transfer to ICU at day 28, depending on study group
Time frame: Up to day 28
Rate of transfer to mechanical ventilation at day 28
Rate of transfer to mechanical ventilation at day 28, depending on study group
Time frame: Up to day 28
Incidence of ARDS at day 28
Incidence of ARDS at day 28, depending on study group
Time frame: Up to day 28
Incidence of death from any cause at day 28
Incidence of death from any cause at day 28, depending on study group
Time frame: Up to day 28
Incidence of symptoms of a secondary bacterial infection
* leukocytosis \> 12x10\^9 / l (in the absence of previous use of glucocorticosteroids), * and / or shift to stab \> 10 %, * and / or purulent sputum or other clinical manifestations of purulent inflammation, * and / or an increase in procalcitonin\> 0.5 ng / ml depending on study group
Time frame: Up to day 28
Time to improvement in clinical status by at least 1 point
Time to improvement in clinical status by at least 1 point (from the moment of drug administration) (median, in days), depending on study group
Time frame: from the moment of drug administration to improvement, up to 28 days
Incidence of improvement in clinical status by at least 1 point on days 3, 5, 7, 10, 14, 21, 28, depending on study group
Incidence of improvement in clinical status by at least 1 point on days 3, 5, 7, 10, 14, 21, 28, depending on study group
Time frame: Up to day 28
Time to reach SpO2 ≥ 95%, without oxygen support for 2 consecutive days
Time to reach SpO2 ≥ 95%, without oxygen support for 2 consecutive days (from the moment of drug administration) (median, in days), depending on study group
Time frame: from the moment of drug administration to the moment when SpO2 ≥ 95%, up to 28 days
Duration of hospitalization at day 28
Duration of hospitalization at day 28 (from the moment of drug administration) (median, in days), depending on study group
Time frame: from the moment of drug administration to discharge, up to 28 days
Duration of ICU stay at day 28
Duration of ICU stay at day 28 (from the moment of drug administration) (median, in days), depending on study group
Time frame: from the moment of drug administration to discharge from ICU, up to 28 days
Time to normalization of temperature
Time to normalization of temperature (body temperature less than 37 °C for 48 hours or more, without taking antipyretics) (from the moment of drug administration) (median, in days), depending on study group
Time frame: from the moment of drug administration to temperature normalization, up to 28 days
Change from baseline of the assessment of the immune status by the Investigator
Change from baseline of the assessment of the immune status by the Investigator, based on clinical course and laboratory markers (- IL-6, - complement components - C3 and C4, T-lymphocytes (CD3 + CD19-); T - helpers (CD3 + CD4 + ); T - cytotoxic lymphocytes (CD3 + CD8); Immunoregulatory index (T-helpers / T-cytotoxic), (CD3 + CD4 + / CD3 + CD8 +); B - lymphocytes (CD3-CD19 +); Activated T-lymphocytes with phenotype (CD3 + HLA-DR +); Lymphocytes with HLA-DR + phenotype, NK cells total (CD3- CD16 + CD56 +); Activated T-cells with markers of NK cells (CD3 + CD56 +).
Time frame: Baseline, day 28
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2021 to primary completion in Oct 2022, 15 months.
Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 15 months is above that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olokizumab